Title: Prevention and Vaccine | Ebola (Ebola Virus Disease) | CDC
Headings: Prevention and Vaccine
Prevention and Vaccine
Ebola Vaccine

Content: Avoid contact with items that may have come in contact with an infected person’s blood or body fluids (such as clothes, bedding, needles, and medical equipment). Avoid funeral or burial practices that involve touching the body of someone who died from EVD or suspect EVD. Avoid contact with bats, forest antelopes, and nonhuman primates (such as monkeys and chimpanzees) blood, fluids, or raw meat prepared from these or unknown animals (bushmeat). These same prevention methods should be used when living in or traveling to an area experiencing an Ebola outbreak. After returning from an area experiencing an Ebola outbreak, people should monitor their health for 21 days and seek medical care immediately if they develop symptoms of EVD. Ebola Vaccine
The U.S. Food and Drug Administration (FDA) approved the Ebola vaccine rVSV-ZEBOV (called Ervebo ®) on December 19, 2019. This is the first FDA-approved vaccine for Ebola. This vaccine is given as a single dose vaccine and has been found to be safe and protective against Zaire ebolavirus, which has caused the largest and most deadly Ebola outbreaks to date. On February 26, 2020, the Advisory Committee on Immunization Practices (ACIP) recommended pre-exposure prophylaxis vaccination with rVSV-ZEBOV for adults ≥ 18 years of age in the U.S. population who are at potential occupational risk of exposure to Zaire ebolavirus. This recommendation includes adults who are
Responding or planning to respond to an outbreak of EVD;